Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses

首次发布于 2001 年 9 月 25 日

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days

首次发布于 2001 年 9 月 25 日

Baker Gordon Syndrome Natural History Study

计划入组 50 人 · 首次发布于 2024 年 5 月 6 日

SS1(dsFv)-PE38

KS18

SS118

SSG HOSPITAL

India

SSP Co., Ltd.

Japan

SGX Pharmaceuticals, Inc.

United States

Adaptimmune's TECELRA Marks First Engineered Cell Therapy Approval for Solid Tumors in Synovial Sarcoma

Trabectedin-Irinotecan Combination Shows Promise Against EWS::FLI1 Fusion in Ewing Sarcoma Phase 1/2 Trial

Multi-Antigen T Cell Therapy Shows 84.6% Disease Control Rate in Pancreatic Cancer Phase 1/2 Trial